C Simard

7.0k total citations · 4 hit papers
22 papers, 1.9k citations indexed

About

C Simard is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Plant Science. According to data from OpenAlex, C Simard has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 3 papers in Surgery and 3 papers in Plant Science. Recurrent topics in C Simard's work include Cystic Fibrosis Research Advances (8 papers), Nematode management and characterization studies (3 papers) and Tracheal and airway disorders (3 papers). C Simard is often cited by papers focused on Cystic Fibrosis Research Advances (8 papers), Nematode management and characterization studies (3 papers) and Tracheal and airway disorders (3 papers). C Simard collaborates with scholars based in United States, United Kingdom and Ireland. C Simard's co-authors include Charlotte McKee, Julie Lekstrom-Himes, Edward P. Ingenito, Jennifer L. Taylor‐Cousar, Elizabeth Tullis, Steven M. Rowe, Cori Daines, À. Munck, Linda T. Wang and Edward F. McKone and has published in prestigious journals such as New England Journal of Medicine, Blood and Thorax.

In The Last Decade

C Simard

18 papers receiving 1.9k citations

Hit Papers

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Hom... 2017 2026 2020 2023 2017 2018 2017 2023 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C Simard United States 7 1.6k 287 203 156 113 22 1.9k
Martin Stern United Kingdom 10 882 0.5× 484 1.7× 342 1.7× 57 0.4× 97 0.9× 16 1.6k
J. R. K. Savage United States 9 606 0.4× 235 0.8× 186 0.9× 59 0.4× 65 0.6× 19 895
Andrew J. Hirsh United States 15 685 0.4× 377 1.3× 200 1.0× 20 0.1× 96 0.8× 18 1.3k
S. Armoni Israel 10 558 0.3× 238 0.8× 92 0.5× 18 0.1× 50 0.4× 19 802
Danieli B. Salinas United States 15 731 0.4× 211 0.7× 113 0.6× 21 0.1× 43 0.4× 24 1.0k
Henk J. Veeze Netherlands 20 802 0.5× 187 0.7× 115 0.6× 20 0.1× 88 0.8× 49 1.6k
Gabriella Wojewodka Canada 17 333 0.2× 295 1.0× 101 0.5× 23 0.1× 87 0.8× 29 868
Kang-Yun Lee Taiwan 18 278 0.2× 265 0.9× 110 0.5× 33 0.2× 82 0.7× 38 1.1k
S. Vamsee Raju United States 16 915 0.6× 210 0.7× 325 1.6× 20 0.1× 118 1.0× 37 1.2k
Stephanie Hirtz Germany 15 814 0.5× 146 0.5× 142 0.7× 10 0.1× 57 0.5× 23 985

Countries citing papers authored by C Simard

Since Specialization
Citations

This map shows the geographic impact of C Simard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Simard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Simard more than expected).

Fields of papers citing papers by C Simard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Simard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Simard. The network helps show where C Simard may publish in the future.

Co-authorship network of co-authors of C Simard

This figure shows the co-authorship network connecting the top 25 collaborators of C Simard. A scholar is included among the top collaborators of C Simard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Simard. C Simard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jones, J. W., Darin Correll, Sandra Lechner, et al.. (2023). Selective Inhibition of Na V 1.8 with VX-548 for Acute Pain. New England Journal of Medicine. 389(5). 393–405. 110 indexed citations breakdown →
2.
Frangoul, Haydar, Franco Locatelli, Monica Bhatia, et al.. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood. 140(Supplement 1). 29–31. 15 indexed citations
3.
Volkova, Nataliya, Kristin A. Moy, Jennifer Evans, et al.. (2019). Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. Journal of Cystic Fibrosis. 19(1). 68–79. 186 indexed citations
4.
Keating, D., Gautham Marigowda, Lucy Burr, et al.. (2018). VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine. 379(17). 1612–1620. 500 indexed citations breakdown →
5.
EVANS, JEFF, David Campbell, Shan Tian, et al.. (2018). IPD2.02 Real-world outcomes in patients with CF treated with ivacaftor: 2016 US and UK CF Registry analyses. Journal of Cystic Fibrosis. 17. S54–S54.
6.
Bessonova, Leona, Nataliya Volkova, Mark Higgins, et al.. (2018). Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 73(8). 731–740. 143 indexed citations
7.
Flume, Patrick A., Julie Lekstrom-Himes, C Simard, et al.. (2018). P021 A phase 3, open-label study of tezacaftor/ivacaftor (TEZ/IVA) therapy: interim analysis of pooled safety, and efficacy in patients homozygous for F508del-CFTR. Journal of Cystic Fibrosis. 17. S64–S65. 2 indexed citations
8.
EVANS, JEFF, David Campbell, Shan Tian, et al.. (2018). IPD2.01 Disease progression in patients with CF treated with ivacaftor: analyses of real-world data from the US and UK CF Registries. Journal of Cystic Fibrosis. 17. S53–S53. 4 indexed citations
9.
Taylor‐Cousar, Jennifer L., À. Munck, Edward F. McKone, et al.. (2017). Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. New England Journal of Medicine. 377(21). 2013–2023. 553 indexed citations breakdown →
10.
Rowe, Steven M., Cori Daines, Felix C. Ringshausen, et al.. (2017). Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. New England Journal of Medicine. 377(21). 2024–2035. 364 indexed citations breakdown →
11.
Verret, J L, et al.. (1983). Pigmentation cutanée induite par la minocycline.. Annales de Dermatologie et de Vénéréologie. 110(9). 2 indexed citations
12.
Simard, C, et al.. (1983). [Skin pigmentation induced by minocycline].. PubMed. 110(9). 777–8. 2 indexed citations
13.
Saint‐André, Jean‐Paul, et al.. (1983). [Chronic atrophic gastritis with carcinoid tumor and microcarcinoidosis. Report of a case with immunohistochemistry and ultrastructure study].. PubMed. 3(3). 235–40. 6 indexed citations
14.
Simard, C, et al.. (1982). [Could isolated mesangial deposits of C3 be responsible of glomerular hematuric nephropathies (author's transl)].. PubMed. 2(2). 159–62. 1 indexed citations
15.
Perreau, P., et al.. (1972). [Gougerot-Sjögren syndrome and glomerulonephritis].. PubMed. 48(14). 973–8. 2 indexed citations
16.
Perreau, P., et al.. (1972). [Primary lithiasis of the small intestine and intestinal tuberculosis].. PubMed. 48(41). 2665–7.
17.
Pillot, J, et al.. (1971). [Histological study of hepatitis observed during treatment with rifampicin (comparison with the results of research on the Australia antigen)].. PubMed. 35(2). 185–96.
18.
Simard, C, et al.. (1970). [Pulmonary allescheriasis (mycetoma due to Allescheria boydii)].. PubMed. 22(4). 425–37. 3 indexed citations
19.
Simard, C, et al.. (1968). [Coexistent reticulum cell sarcoma and chronic myeloid leukemia].. PubMed. 76(4). 169–72. 3 indexed citations
20.
Simard, C, et al.. (1961). [Multiple glomus tumors].. PubMed. 9. 236–40. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026